readthroughSign in
Nov 16, 2026FinancingUpdated

Vir Biotechnology refiles prospectus supplement to add omitted exhibit

The company corrected its November 12 prospectus supplement filing after inadvertently omitting Exhibit 107, with no other changes to the stock offering terms.

Vir Biotechnology, Inc. filed a supplement to its prospectus supplement on November 16, 2026, solely to add a missing exhibit. The filing states the company is making this filing pursuant to Rule 424(b)(5) under the Securities Act of 1933 as a supplement to its prospectus supplement dated November 12, 2026 to the prospectus dated November 12, 2026, originally filed with the SEC on November 16, 2026, solely for the purpose of including Exhibit 107 required under 17 CFR § 229.601(b)(107)1. The company explained that it inadvertently omitted Exhibit 107 from the Original Filing1. The filing notes that except as described above, no changes have been made to the Original Filing, and this filing does not modify, amend or update any of the other information contained in the Original Filing1.

The underlying offering terms remain as previously disclosed. Vir Biotechnology entered into an underwriting agreement on November 12, 2026 with Leerink Partners LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C. for the sale of 15,000,000 shares of common stock of Vir Bio, par value $0.0001 per share, at a price to the public of $10.00 per share2. The offering was expected to close on November 16, 2026, subject to the satisfaction of customary closing conditions2.

The underwriters also hold an option. Vir Biotechnology granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,250,000 shares of Common Stock at the public offering price2. The company expects to receive net proceeds from the Offering of approximately $140.4 million, or approximately $161.5 million if the Underwriters exercise in full their option to purchase additional shares, after deducting underwriting discounts and commissions and estimated Offering expenses2.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.